Tolero Pharmaceuticals to Present Updates on Clinical and Preclinical Programs at the AACR Annual Meeting 2016

SALT LAKE CITY–(BUSINESS WIRE)–Tolero Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for oncology and hematologic diseases, announced today that it will present two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana, April 16 through 20, 2016. The presentations include nonclinical results that further support the development of Tolero’s clinical and preclinical pipeline agents, including the CDK9 inhibitor (alvocidib) and the AXL kinase inhibitor (TP-0903).
Details of the poster presentations are as follows:
Abstract: #5547
Title: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies
Presenter: Cliff Whatcott
Session Title: Cellular Processes and Responses to Therapy
Date: Sunday, April 17, 2016
Presentation Time: 1:00 PM-5:00 PM CT
Location: Convention Center, Halls G-J, Poster Section 14
Abstract: #5462
Title: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations
Presenter: Adam Siddiqui
Session Title: Cell Death Pathways and DNA Repair
Date: Tuesday, April 19, 2016
Presentation Time: 1:00 PM-5:00 PM CT
Location: Convention Center, Halls G-J, Poster Section 14
About Alvocidib
Alvocidib is a potent, small-molecule inhibitor of cyclin-dependent kinase 9 (CDK9) in development as a combination therapy for frontline and relapsed/refractory acute myeloid leukemia (AML). CDK9 is a protein critical to the regulation of gene expression including the MCL-1 gene and other important genes involved in cancer. Given the key role CDK9 de-regulation plays in expression of cancer-associated genes related to cell division and proliferation, CDK9 is an attractive target for the treatment of various cancers.
About Tolero
Tolero Pharmaceuticals is a clinical stage biopharmaceutical company developing treatments to improve and extend the lives of patients with cancer and blood diseases. Our diverse pipeline targets important biological drivers of blood disorders to treat leukemias and anemia as well as important targets of drug resistance and transcriptional control.